In8Bio (INAB) Accumulated Expenses (2020 - 2026)
In8Bio (INAB) posted Accumulated Expenses of $353000.0 for Q1 2026, down 72.95% sequentially from $1.3 million in Q4 2025, and up 206.96% YoY from $115000.0 in Q1 2025.
In8Bio (INAB) Accumulated Expenses (2020 - 2026) Analysis & Trends
In8Bio has reported Accumulated Expenses for 7 years, with the latest figure at $353000.0 in Q1 2026.
- Quarterly Accumulated Expenses rose 206.96% year-over-year to $353000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $353000.0 (up 206.96% YoY) and the FY2025 annual result came in at $1.3 million, up 24.64% from the prior year.
- Accumulated Expenses fell to $353000.0 in Q1 2026 per INAB's latest filing, from $1.3 million in the prior quarter.
- Over five years, Accumulated Expenses peaked at $2.9 million in Q3 2022 and troughed at $115000.0 in Q1 2025.
- A 5-year average of $1.2 million and a median of $895000.0 in 2024 frame the typical range for Accumulated Expenses.
- The sharpest annual moves came in 2022 and 2025: Accumulated Expenses surged 348.53% in 2022, then slumped 87.15% in 2025.
- Over 5 years, Accumulated Expenses stood at $2.3 million in 2022, then slipped by 28.57% to $1.7 million in 2023, then slumped by 37.42% to $1.0 million in 2024, then rose by 24.64% to $1.3 million in 2025, then sank by 72.95% to $353000.0 in 2026.
- According to Business Quant data, Accumulated Expenses over the past three periods registered $353000.0, $1.3 million, and $300000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | In8Bio | 24.34 Mn | 24.34 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 761,000.00 |
| Mar 31, 2026 | 353,000.00 |
| Dec 31, 2025 | 1.31 Mn |
| Sep 30, 2025 | 300,000.00 |
| Jun 30, 2025 | 635,000.00 |
| Mar 31, 2025 | 115,000.00 |
| Dec 31, 2024 | 1.05 Mn |
| Sep 30, 2024 | 769,000.00 |
| Jun 30, 2024 | 1.53 Mn |
| Mar 31, 2024 | 895,000.00 |
| Dec 31, 2023 | 1.67 Mn |
| Sep 30, 2023 | 2.44 Mn |
| Jun 30, 2023 | 852,000.00 |
| Mar 31, 2023 | 422,000.00 |
| Dec 31, 2022 | 2.34 Mn |
| Sep 30, 2022 | 2.88 Mn |
| Jun 30, 2022 | 1.53 Mn |
| Mar 31, 2022 | 884,000.00 |
| Dec 31, 2021 | 926,000.00 |
| Sep 30, 2021 | 840,000.00 |